Objective: The aim of this study was to assess the impact of regularity in treatment follow-up appointments on treatment outcomes among hypertensive patients attending different healthcare settings in Islamabad, Pakistan. Additionally, factors associated with regularity in treatment follow-up were also identified.Methods: A cross-sectional study was undertaken in selected primary, secondary and tertiary healthcare settings between September, 2017 and December, 2018 in Islamabad, Pakistan. A structured data collection form was used to gather sociodemographic and clinical data of recruited patients. Binary logistic regression analyses were undertaken to determine association between regularity in treatment follow-up appointments and blood pressure control and to determine covariates significantly associated with regularity in treatment follow-up appointments.Results: A total of 662 patients with hypertension participated in the study. More than half 346 (52%) of the patients were females. The mean age of participants was 54 ± 12 years. Only 274 (41%) patients regularly attended treatment follow-up appointments. Regression analysis found that regular treatment follow-up was an independent predictor of controlled blood pressure (OR 1.561 [95% CI 1.102–2.211;P = 0.024]). Gender (OR 1.720 [95% CI 1.259–2.350;P = 0.001]), age (OR 1.462 [CI 95%:1.059–2.020;P = 0.021]), higher education (OR 1.7 [95% CI 1.041–2.778;P = 0.034]), entitlement to free medical care (OR 3.166 [95% CI 2.284–4.388;P = 0.0001]), treatment duration (OR 1.788 [95% CI 1.288–2.483;P = 0.001]), number of medications (OR 1.585 [95% CI 1.259–1.996;P = 0.0001]), presence of co-morbidity (OR 3.214 [95% CI 2.248–4.593;P = 0.0001]) and medication adherence (OR 6.231 [95% CI 4.264–9.106;P = 0.0001]) were significantly associated with regularity in treatment follow-up appointments.Conclusion: Attendance at follow-up visits was alarmingly low among patients with hypertension in Pakistan which may explain poor treatment outcomes in patients. Evidence-based targeted interventions should be developed and implemented, considering local needs, to improve attendance at treatment follow-up appointments.
1 January 2020 in Patient Preference and Adherence
Objective: This study aimed to assess the prevalence and predictors of non-adherence to antihypertensive medication among patients with hypertension attending various healthcare settings in Islamabad, Pakistan. Methods: A questionnaire-based cross-sectional study was conducted in selected healthcare facilities between September 2017 and December 2018. The study was conducted in primary, secondary and tertiary healthcare settings in Islamabad, Pakistan. Medication adherence was assessed using the eight-item Morisky Medication Adherence Scale (MMAS-8). Sociodemographic and clinical data of recruited patients were collected through a structured questionnaire. Binary logistic regression analysis was performed to determine covariates significantly associated with medication adherence and blood pressure control. Results: A total of 776 hypertensive patients were invited and 741 (95%) completed the questionnaire. The mean ± SD age of participants was 53.6± 12.6 years; 284 patients (38.3%) had high adherence, 178 (24%) had moderate adherence and 279 (37.7%) were non-adherent to the prescribed antihypertensive therapy. Binary regression analysis revealed that old age (OR 1.783 [95% CI: 1.172– 2.712]; P=0.013), being educated (OR 2.018 [95% CI: 1.240– 3.284]; P=0.036), entitlement to free medical care (OR 1.369 [95% CI: 1.009– 1.859]; P=0.044), treatment duration (OR 2.868 [95% CI: 1.913– 4.299]; P=0.001), number of medications (OR 1.973 [95% CI: 1.560– 2.495]; P=0.001), presence of any comorbidity (OR 2.658 [95% CI: 1.836– 3.848]; P=0.001) and blood pressure control (OR 3.103 [95% CI: 2.268– 4.247]; P=0.001) were significantly associated with good adherence. Similarly, age (OR 1.998 [95% CI: 1.313– 3.040]; P=0.004), entitlement to free medical care (OR 1.498 [95% CI: 1.116– 2.010]; P=0.007), treatment duration (OR 1.886 [95% CI: 1.143– 3.113]; P=0.013), presence of any comorbidity (OR 1.552 [95% CI: 1.123– 2.147]; P=0.008) and adherence level (OR 3.103 [95% CI: 2.268– 4.247]; P=0.001) had significant association with controlled blood pressure. The following were the main reasons for non-adherence to prescribed antihypertensive medication: “don’t feel need for regular use“ (24.7%), “Carelessness“ (13.4%) and “adverse effects“ (11.2%). Conclusion: The prevalence of non-adherence to antihypertensive medications was high in the study population and poor medication adherence could potentially explain poor blood pressure control. Evidence-based targeted interventions on both medication adherence and blood pressure control should be introduced and implemented for better treatment outcomes.
A systematic review was performed to estimate the duration of protection of Hepatitis-B vaccine after primary vaccination during infancy. The number of seropositive participants with anti-HBs antibody titer ≥ 10 mIU/ml and seronegative participants who had anti-HBs antibody titer ≤ 10 mIU/ml after booster dose was the main outcome criteria to find out the protection time of Hepatitis-B vaccine. Twelve studies were selected for systematic review. Overall, results from the meta-analysis have revealed that the risk of Anti-HBs Titer ≤ 10 mIU/ml reduced by 50%. Upon performing the sub-group analysis it was revealed that the overall risk of having Anti-HBs Titre ≤ 10 mIU/ml was reduced up to 62% among the subjects age 21–30 years (0.38 [0.34, 0.44]; I2 = 0.0%, p = 0.938). Furthermore, it was observed that the risk of having titre level less than 10 mIU/ml for plasma derived vaccines were to be 56% [0.44, CI 0.33–0.57, I2 90.9%, p = <0.001]. Vaccination in early infancy does not ensure protection against Hepatitis-B infection. There is a strong correlation between the duration of protection and time elapsed after primary immunization during infancy.
1 December 2017 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Pharmacists deliver pharmaceutical care in many different healthcare settings and are well-placed to support the prevention of stroke. However, their role and impact in this area is ill-defined. This systematic review aims to explore the pharmacists’ role in stroke prevention. Nine databases were searched for studies reporting pharmacist interventions in the management of primary and secondary ischaemic stroke prevention. Study quality was evaluated through Cochrane Risk of Bias and Joanna Briggs Institute (JBI) appraisal tools where possible. A narrative review was conducted and meta-analysis performed for studies with comparable outcomes. Of the 834 initial articles, 31 met inclusion criteria. Study designs were varied and included controlled trials, observational studies, audit reports and conference abstracts. Seven studies addressed the pharmacists’ role in primary prevention and 24 in secondary prevention. Pharmacist interventions reported were diverse and often multifactorial. Overall, 20 studies reported significant improvement in outcomes. Meta-analysis showed pharmacist interventions in emergency care significantly improved the odds of achieving thrombolytic therapy door to needle (DTN) times ≤45 min, odds ratio: 2.69 (95% confidence interval (CI): 1.95–3.72); p < 0.001. The pharmacists’ role is varied and spans the stroke treatment pathway, with the potential for a positive impact on a range of health-related outcomes.
About Me
Dr Sajid is working as assistant professor in Clinical Pharmacy.
Dr Sajid is working as assistant professor in Clinical Pharmacy.